Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | UGCG | Q16739 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4684572 | 0.99 | ENPP2 (0.53) | ENPP2ATXN2L3MBTL1UGCGKMT2A | |
| SCHEMBL543229 | 0.87 | HTR2C (0.52) | ENPP2ATXN2KMT2AMEN1MAPT | |
| SCHEMBL4678280 | 0.87 | ALDH1A1 (0.47) | ENPP2ATXN2L3MBTL1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL4682111 | 0.86 | GRIN2B (0.47) | ENPP2ATXN2L3MBTL1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL4682149 | 0.86 | HTR2C (0.51) | ENPP2ATXN2KMT2AMEN1MAPT | |
| SCHEMBL542695 | 0.83 | ALDH1A1 (0.54) | ENPP2L3MBTL1KMT2AMEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL4684877 | 0.82 | ALDH1A1 (0.53) | ENPP2L3MBTL1KMT2AMEN1CYP1A2 | |
| SCHEMBL543619 | 0.82 | HTR3E (0.50) | KMT2AGAATSHRCYP2C19HRH4 | |
| SCHEMBL20827277 | 0.81 | EPHX2 (0.63) | ENPP2ATXN2CYP2C19CYP2C9MAPT | |
| SCHEMBL148277 | 0.80 | SCN5A (0.50) | ENPP2ATXN2KMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414330-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-02-08 | — | — | EP | claimed |
| WO-2010115491-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-14 | — | — | WO | claimed |
| EP-2414330-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010115491-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | ENPP2 4317/4885ATXN2 2847/4885L3MBTL1 2739/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | ENPP2 4317/4885ATXN2 2847/4885L3MBTL1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.